Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis

NCT06690242 is registered in ClinicalTrials.gov with Shaanxi Micot Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06690242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06690242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2024
Completion date
August 30, 2025
Enrollment
115 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism (shpt) in subjects with chronic kidney disease (ckd) on hemodialysis